Drug-Induced QT Prolongation in the Emergency Department

Drug-induced QT prolongation is a frequent emergency department problem, but its clinical significance is easy to overstate or miss. A long QT interval can provide the substrate for torsades de pointes, a polymorphic ventricular tachycardia that may terminate spontaneously, cause syncope, or deteriorate into ventricular fibrillation. The immediate task is to distinguish an incidental electrocardiographic finding from a preventable, evolving arrhythmic emergency.

Risk is shaped by the interaction between a medicine and the patient receiving it. Renal impairment, bradycardia, hypokalaemia, hypomagnesaemia, structural heart disease, acute illness, and combinations of QT-prolonging agents can convert a modest change in repolarisation into a dangerous one. The absolute QTc value matters, but the clinical context matters just as much.

For clinicians working in Australia, decisions may involve medicines supplied through the local market, including sotalol, amiodarone, methadone, haloperidol, macrolides, fluoroquinolones, and ondansetron. The emergency environment also varies widely, from a tertiary cardiac service in Melbourne or Sydney to a regional hospital coordinating retrieval over long distances. A practical approach must therefore combine risk prediction with rapid bedside mitigation.

Why QT prolongation becomes dangerous

The QT interval represents ventricular depolarisation and repolarisation. Because it changes with heart rate, clinicians generally use a corrected QT interval, or QTc. Bazett’s formula is common on automated ECG reports, but it can overcorrect at faster rates and undercorrect at slower rates. Fridericia’s formula is often more reliable when the heart rate is substantially abnormal. Automated measurements should be checked manually, particularly when the T wave is broad, biphasic, notched, or merged with a U wave.

A QTc above 500 milliseconds is widely treated as a high-risk marker, while an increase of more than 60 milliseconds from baseline is concerning even when the absolute value remains below 500 milliseconds. Neither threshold predicts torsades with certainty. Bradycardia, pauses, ventricular ectopy, and a history of syncope or drug-induced arrhythmia may be more clinically important than a borderline isolated value. A wide QRS from bundle branch block or ventricular pacing also complicates interpretation, because the prolonged QT may partly reflect delayed depolarisation rather than prolonged repolarisation.

The danger usually emerges through several converging factors. A patient taking a QT-active drug who presents with vomiting may have lost potassium and magnesium; a patient with sepsis may develop renal dysfunction and receive another interacting medicine; a person on methadone may also take an antidepressant or an antibiotic that inhibits metabolism. The resulting risk is dynamic, so an ECG obtained at triage may not represent the patient’s worst repolarisation later in the visit.

Using risk scores without false reassurance

The Tisdale risk score is the best-known structured tool for predicting QT prolongation in hospitalised patients. Its variables include older age, female sex, low serum potassium, baseline QTc prolongation, heart failure, acute myocardial infarction, sepsis, loop diuretic use, and exposure to one or more QT-prolonging drugs. Scores are commonly grouped as low, moderate, or high risk, with higher scores supporting telemetry, medication review, and repeat ECG testing.

The score was developed primarily in inpatients, not as a definitive emergency department rule. Its performance can be less certain in overdose, paediatric presentations, pregnancy, severe tachycardia, and patients with paced rhythms or marked QRS widening. A low score should not override a QTc above 500 milliseconds, recurrent syncope, ventricular ectopy, or an obvious high-risk drug interaction. Conversely, a high score identifies the need for attention; it does not establish that torsades will occur.

A sensible ED workflow uses the score as a prompt rather than a gatekeeper. Record the presenting ECG, medication exposure, renal function, potassium, magnesium, calcium, heart rate, and relevant cardiac history. Recalculate risk when the patient’s physiology changes or a new medicine is prescribed. When an overdose is suspected, toxicology guidance and serial ECGs are more useful than relying on a score validated for routine hospital prescribing.

Resources from the Journal of Arrhythmia can complement local protocols, particularly when an ED team needs to connect acute management with electrophysiology evidence. Risk tools are most effective when they support a consistent process for identifying hazards, communicating them during handover, and documenting why a medicine was withheld or substituted.

Finding the medication and patient hazards

Medication reconciliation should include prescribed medicines, over-the-counter products, recent antibiotics, opioid substitution therapy, recreational drugs, and medicines administered before arrival. The Australian market includes several commonly used agents with clinically relevant repolarisation effects. Sotalol and dofetilide, where available, require particular caution; amiodarone prolongs QT but has a comparatively lower torsades rate than many other QT-active drugs, although it remains capable of causing proarrhythmia. Haloperidol, methadone, ondansetron, azithromycin, and some fluoroquinolones deserve attention when risk factors cluster.

The Therapeutic Goods Administration product information, hospital formulary, Australian Medicines Handbook, and a specialist QT-drug database can help clarify dose-related effects and interactions. A medicine’s classification is not a substitute for clinical judgement: risk may increase with renal accumulation, rapid intravenous administration, high cumulative dose, or co-prescription of another agent. In a busy emergency department in Brisbane during a hot summer, dehydration and gastrointestinal losses may be the decisive factors in a patient whose medication list appears stable.

Assess for previous long QT syndrome, unexplained sudden death in the family, unexplained seizure or syncope, cardiomyopathy, recent myocardial infarction, and impaired kidney or liver function. Ask about palpitations and collapse rather than relying on the presenting complaint alone. Patients who use methadone may need a careful balance between arrhythmia prevention and withdrawal management; abrupt interruption can create its own clinical problems, so consultation with toxicology, addiction medicine, or cardiology may be appropriate.

Correcting reversible factors quickly

The first mitigation step is to stop or defer non-essential QT-prolonging medicines. Replace them with an effective alternative when possible, especially if the patient has a markedly prolonged QTc, ventricular ectopy, or several simultaneous risk factors. Review the entire prescribing plan rather than focusing only on the newest drug. An antibiotic, antiemetic, antipsychotic, and home antiarrhythmic may each seem defensible in isolation while creating substantial combined exposure.

Correct potassium, magnesium, and calcium abnormalities promptly. Many services aim for potassium in the high-normal range, often above 4.0 mmol/L, and magnesium at or above the normal range in patients at significant risk, while avoiding inappropriate replacement in advanced renal failure. Intravenous magnesium is the immediate treatment for torsades de pointes, even when the serum magnesium concentration is normal. Defibrillation is required for pulseless or unstable ventricular tachycardia; magnesium should never delay electricity when the patient is haemodynamically compromised.

Continuous cardiac monitoring is appropriate for marked QTc prolongation, syncope with concerning ECG findings, ventricular ectopy, significant overdose, or the need to continue an essential QT-active medicine. Repeat the ECG after electrolyte correction, drug clearance, or a major clinical change. In a Perth or Darwin hospital without immediate electrophysiology cover, early consultation with the regional cardiology service and a clear escalation plan are particularly important. Remote advice and retrieval planning should begin before recurrent arrhythmia makes transfer urgent.

Building safer emergency pathways

A reliable pathway starts at triage or the first prescribing decision. Obtain an ECG before giving a QT-active medicine when the patient has a relevant history, takes several interacting drugs, or has electrolyte loss, renal failure, bradycardia, or unexplained collapse. This should be targeted rather than an impractical demand for an ECG before every dose. The result must be visible to the treating team and linked to a plan for repeat assessment.

When a patient has QTc prolongation, document the suspected cause, the medicines stopped or substituted, electrolyte targets, monitoring location, and criteria for discharge. A patient with a modest, improving QTc and corrected abnormalities may be suitable for discharge with medication review and follow-up. A patient with persistent QTc above 500 milliseconds, syncope, ventricular ectopy, ongoing exposure, or suspected inherited long QT syndrome generally needs senior review and an appropriate monitored setting.

Communication at transitions is a recurrent weak point. Include the last ECG, maximum QTc, electrolyte results, suspected culprit medicines, and the timing of the next ECG in the handover. For patients transferred from a rural facility to a metropolitan centre, this information can be more valuable than a generic statement that the ECG was “abnormal.” Protocols should also specify who reviews the medication list after discharge, since primary care, addiction services, pharmacy, and cardiology may each hold part of the solution.

Specialist literature can sharpen these pathways. For example, research on procedural durability, including cryoballoon durability findings, illustrates how electrophysiology practice depends on identifying predictors, measuring outcomes, and applying evidence to individual patients. The same discipline applies in the ED: identify modifiable predictors, measure the response, and escalate when the trajectory remains unsafe.

Extending learning beyond a single presentation

QT safety improves when cases are reviewed across departments rather than treated as isolated prescribing errors. A short audit can examine how often QTc was recorded before high-risk medicines, whether electrolytes were corrected, how frequently repeat ECGs occurred, and whether medication changes were communicated at discharge. Reviewing near misses, such as a patient who developed ventricular ectopy without progressing to torsades, can reveal system weaknesses before a catastrophic event.

Education should include ECG interpretation, limitations of automated QTc values, drug interactions, and the management of torsades. Simulation is useful for rehearsing the sequence of stopping offending medicines, giving magnesium, correcting potassium, managing bradycardia, and defibrillating an unstable patient. Junior doctors, nurses, pharmacists, and paramedics each encounter different parts of the risk pathway, so shared terminology improves safety.

Australian clinicians can use thematic collections to locate focused research and educational material on arrhythmia care, pacing, pharmacology, and electrophysiology. Local governance groups should translate relevant evidence into practical order sets and escalation criteria rather than distributing unreviewed lists of “safe” and “unsafe” medicines. Drugs change, patient factors change, and the risk is always relational.

Use a structured QT assessment for every high-risk presentation, verify the ECG rather than accepting an unexplained automated result, correct potassium and magnesium early, and remove avoidable medication combinations. Embed these steps in ED protocols, pharmacy review, handover, and discharge documentation so that prevention continues after the acute episode. Consistent application turns QT prolongation from a late warning sign into an opportunity to prevent torsades, cardiac arrest, and repeat presentation.